UPDATE: Oppenheimer Starts Cincor Pharma Inc (CINC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evercore ISI Starts Cincor Pharma Inc (CINC) at Outperform
February 1, 2022 6:33 AM ESTEvercore ISI analyst Michael DiFiore initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Outperform rating.
The analyst comments "Cincor is a cardio-renal-focused company whose only drug (CIN-107) a highly selective/potent inhibitor of aldosterone synthase, the enzyme that catalyzes the formation of aldosterone.... More
UPDATE: Jefferies Starts Cincor Pharma Inc (CINC) at Buy
February 1, 2022 3:52 AM EST(Updated - February 1, 2022 4:52 AM EST)
Jefferies analyst Dennis Ding initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Buy rating and a price target of $30.00.
The analyst comments "CINC has a differentiated pill, CIN-107, for difficult to... More
UPDATE: Morgan Stanley Starts Cincor Pharma Inc (CINC) at Overweight
February 1, 2022 3:13 AM EST(Updated - February 1, 2022 5:53 AM EST)
Morgan Stanley analyst Jeffrey Hung initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Overweight rating and a price target of $27.00.
The analyst comments "CIN-107 initial data demonstrate a targeted approach with a favorable... More
